Why Thousands Are Using This Needle-Free Breakthrough For Weight Loss – Before the Holiday Rush
(Note: Thank you for supporting businesses like the one presenting a sponsored message below and working with them through the links below which benefits Gateway Pundit. We appreciate your support!) The holidays will be here in a flash — feasts, parties, and extra treats all beckoning. It’s easy to tell yourself: “I’ll start in January.” […]
Top Research Reports for Microsoft, Amazon.com & Eli Lilly
Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), Amazon.com, Inc. (AMZN) and Eli Lilly and Co. (LLY). These research reports have been hand-picked from the roughly 70 reports published by our […]
STAT+: Novo Nordisk’s $199 Ozempic deal shows what telehealth platforms can do for pharma
On Monday, Novo Nordisk announced a discount on its popular drugs for diabetes and obesity, Ozempic and Wegovy, cutting prices for the lowest doses to $199 when patients pay cash through Novo’s pharmacy NovoCare. Patients searching for those deals online, though, won’t always get funneled to the drugmaker’s sites. Instead, the first results they may […]
Tech Tracker: DoorDash confirms data security incident
Plus, a profile on the latest startup challenging the dominance of DoorDash and Uber Eats, and a new GLP-1 menu tool
Why Big Pharma Won’t Quit the Diet. Who Will Win the Next Weight Loss Battle?
Key Points Weight loss pills could account for 25% of the market share over the long term. The GLP-1 market is expected to grow to $100 billion by 2030. New GLP-1 oral versions could receive FDA approval by the end of 2025. These 10 stocks could mint the next wave of millionaires › Chances are […]
Gallego demands answers on Eli Lilly’s deal with Trump
Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly CEO David Ricks, provided first to The Hill, Gallego wrote that “substantial questions remain” pertaining to the deal that the White House struck with…
Drug Cuts Nausea From GLP-1 Drugs; ‘Female Viagra’ Boom; Semaglutide and Alcohol Use
(MedPage Today) — Vanda Pharmaceuticals said its investigational neurokinin-1 receptor antagonist tradipitant reduced nausea and vomiting from semaglutide (Ozempic, Wegovy) in a randomized trial of people with obesity or overweight. A KFF poll…
Brain Activity on Zepbound; Alzheimer’s and Chris Hemsworth; Autism-Gut Link Queried
(MedPage Today) — Intracranial electroencephalography measured the brain activity of a patient with obesity and loss-of-control eating after taking tirzepatide (Zepbound), showing the medication suppressed brain signaling associated with food…
How Ozempic Is Changing Thanksgiving
Thanks to the GLP-1 revolution, families across the country are negotiating new ways to connect over the holidays.
Factor in Eli Lilly weight-loss drug could help treat certain eating disorders, study finds
Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the “reward center” of the brain.